Thought to be one of the world’s most prominent medical device manufacturers, Terumo Corporation has forged a strategic partnership with Orchestra BioMed™ to facilitate the development and commercialisation of Virtue® Sirolimus-Eluting Balloons (SEB).
The Virtue SEB aids the prevention of restenosis following a percutaneous interventional surgery by delivering a patented bioabsorbable, sustained-release of sirolimus. The Virtue SEB tool will be the first and only one of its kind in the world, being a non-coated drug-eluting angioplasty balloon device.
As a result of the global partnership, Terumo will be able to expand its global presence and portfolio of interventional surgery solutions, whilst giving Orchestra BioMed the opportunity to establish itself in the biomedical innovation field and create new alliances with other market leaders.
Chairman and chief executive officer of Orchestra BioMed, David Hochman, said: “We are delighted to be aligning with Terumo, which has a rich history of global leadership in medical devices. Terumo has a proven global distribution and operations infrastructure with the sales and marketing expertise necessary to make Virtue SEB broadly accessible to physicians and patients worldwide, pending regulatory approvals.
“This strategic partnership is a major milestone for Orchestra BioMed. It validates our differentiated strategy to focus on the development of high-impact therapies while leveraging alliances with established market leaders, like Terumo, to drive global commercialisation of our products.”